RSV infections: State of the art

Cleveland Clinic Journal of Medicine

Volumn 82, Issue , 2015, Pages 13-18

  Piedimonte, Giovanni ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

CLASSIFICATION; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTOR; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS; UNITED STATES;

EID: 84973408329     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/CCJM.82.S1.03     Document Type: Article

References (22)

1. 1. Peters TR, Crowe JE Jr. Respiratory syncytial virus. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadelphia, PA: Churchill Living-stone/Elsevier; 2008.
2. 2. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014; 35:519–530.
3. 3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440–1446.
4. 4. Simoes EA, Rieger CHL. RSV infection in developed and developing countries. Infect Med 1999; 16:S11–S17.
5. 5. Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune system in very low birth weight (less than 1,500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986; 20:899 –904.
6. 6. Sabogal C, Auais A, Napchan G, et al. Effect of respiratory syncytial virus on apnea in weanling rats. Pediatr Res 2005; 57:819–825.
7. 7. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr 1984; 105:358–364.
8. 8. Henry RL, Hodges IGC, Milner AD, Stokes GM. Respiratory problems 2 years after acute bronchiolitis in infancy. Arch Dis Child 1983; 58:713–716.
9. 9. Webb MSC, Henry RL, Milner AD, Stokes GM, Swarbrick AS. Continuing respiratory problems three and a half years after acute viral bronchiolitis. Arch Dis Child 1985; 60:1064–1067.
10. 10. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161:1501–1507.
11. 11. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171:137–141.
12. 12. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65:1045–1052.
13. 13. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press; 1990:1045.
14. 14. Committee on Infectious Diseases. American Academy of Pediatrics: use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993; 92:501–504.
15. 15. Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996; 97:137–140.
16. 16. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol 2011; 46:324–347.
17. 17. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory synctial virus infection in high-risk infants. Pediatrics 1998; 102(3 Pt 1):531–537.
18. 18. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134:e1474–e1502.
19. 19. Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368:1791–1799.
20. 20. Rezaee F, Gibson LF, Piktel D, Othumpangat S, Piedimonte G. Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol 2011; 45:277–286.
21. 21. Das B, Kashino SS, Pulu I, et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013; 5:170ra13.
22. 22. Piedimonte G, Perez MK. Alternative mechanisms for respiratory syncytial virus (RSV) infection and persistence: could RSV be transmitted through the placenta and persist into developing fetal lungs? Curr Opin Pharmacol 2014; 16:82–88.